Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs
9.1.2026 04:31:00 CET | Business Wire | Press release
A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/

Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation.
Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app.
AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Designed to address common, everyday health concerns and support healthy habit formation, AQ focuses on users’ routine health needs that don’t yet require a hospital visit. Check out this video to see how it works:
https://www.youtube.com/shorts/mZwB0djjcDo
The platform connects users to digital services from 5,000 hospitals, online consultations with 300,000 doctors nationwide, and assistance from over 500 AI Doctor Agents co-developed with top physicians and key hospital departments across China.
Although AQ does not provide medical diagnoses or replace licensed physicians, doctors surveyed said they value AI doctor services for their ability to handle large volumes of patient questions without time or location constraints. Respondents noted that AI systems draw on extensive domain knowledge, can handle large volumes of consultations, respond patiently, and help ease patient anxiety—particularly for routine or repetitive inquiries.
AQ has also partnered with leading physicians across China to launch their AI Doctor Agents on the platform. These agents are trained on each doctor’s clinical experience and provide free responses to users’ health questions. Collectively, the AI Doctor Agents have answered more than 27 million health inquiries in 2025.
One example is Mao Hongjing, Deputy Director of Hangzhou Seventh People’s Hospital and a nationally recognized sleep specialist. Before adopting AI, Mao could treat roughly 10,000 patients per year in person. In contrast, his AI Doctor Agent on AQ has responded to inquiries from 3.68 million users within a single year.
Beyond patient-facing use, the survey found that over 60% of doctors already use AI doctor services to support their work, while over 90% are optimistic about the future development of AI doctors.
The use of AI in healthcare is taking place against the backdrop of China’s demographic shift. According to the National Bureau of Statistics, by the end of 2024, China had 310 million people aged 60 or above, accounting for 22% of the population. Projections from the World Health Organization indicate that this share could rise to nearly 28% by 2040.
An aging population is expected to drive greater demand for healthcare services. According to Grand View Research, China’s AI in healthcare market is projected to grow from US$ 1.6 billion in 2023 to nearly US$ 19 billion by 2030.
To meet this rising demand, hospitals and physicians across China are partnering with technology companies to explore how AI can improve healthcare efficiency while expanding access to quality medical services for a broader population.
About Ant Group
Ant Group is a global digital technology provider and the operator of Alipay, a leading internet services platform in China, connecting over one billion users to more than 10,000 types of consumer services from partners. Through innovative products and solutions powered by AI, blockchain and other technologies, Ant Group supports partners across industries to thrive through digital transformation in an ecosystem for inclusive and sustainable development. For more information, visit www.antgroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108456917/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom